$3.63
3.20% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US09071M1062
Symbol
BLRX

Bioline RX Ltd Sponsored ADR Stock price

$3.63
-0.21 5.47% 1M
+0.47 14.87% 6M
-4.93 57.59% YTD
-21.69 85.67% 1Y
-56.37 93.95% 3Y
-66.77 94.84% 5Y
-1,010.37 99.64% 10Y
-3,350.37 99.89% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.12 3.20%
ISIN
US09071M1062
Symbol
BLRX
Industry

Key metrics

Basic
Market capitalization
$15.9m
Enterprise Value
$3.2m
Net debt
positive
Cash
$26.4m
Shares outstanding
2.2b
Valuation (TTM | estimate)
P/E
- | negative
P/S
0.7 | 7.0
EV/Sales
0.1 | 2.1
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
34.6%
Return on Equity
-68.5%
ROCE
-61.0%
ROIC
-
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$22.3m | $2.6m
EBITDA
$-14.6m | $-10.4m
EBIT
$-18.0m | -
Net Income
$-3.4m | $-22.3m
Free Cash Flow
$-32.4m
Growth (TTM | estimate)
Revenue
91.6% | -91.1%
EBITDA
66.5% | 44.2%
EBIT
60.6% | -
Net Income
93.1% | -142.2%
Free Cash Flow
-12.0%
Margin (TTM | estimate)
Gross
64.9%
EBITDA
-65.6% | -402.5%
EBIT
-80.5%
Net
-15.2% | -864.1%
Free Cash Flow
-144.9%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
4.8%
Employees
-
Rev per Employee
-
Show more

Is Bioline RX Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
22 22
92% 92%
100%
- Direct Costs 7.84 7.84
52% 52%
35%
15 15
123% 123%
65%
- Selling and Administrative Expenses 23 23
32% 32%
104%
- Research and Development Expense 8.28 8.28
27% 27%
37%
-15 -15
66% 66%
-66%
- Depreciation and Amortization 3.33 3.33
65% 65%
15%
EBIT (Operating Income) EBIT -18 -18
61% 61%
-80%
Net Profit -3.40 -3.40
93% 93%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Bioline RX Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioline RX Ltd Sponsored ADR Stock News

Neutral
Seeking Alpha
20 days ago
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.
Neutral
PRNewsWire
21 days ago
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel , Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX),...
Neutral
PRNewsWire
28 days ago
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.
More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office Israel
CEO Mr. Serlin
Founded 2003
Website www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today